Pharmaceutical regulation

The life sciences sector encompasses companies in the fields of pharmaceuticals, biotechnology and medical technology that focus on the research, development and commercialisation of a wide range of products that have a medical application. Such products include pharmaceuticals (ie everything from over-the-counter painkillers to advanced therapies for treating diseases such as cancer or HIV), medical devices (eg plasters, syringes, heart stents, pacemakers, etc) and diagnostics. This subtopic provides an overview of pharmaceutical regulation in the EU.

In the EU, a large amount of the regulation originates from directives or regulations and is supplemented by guidance issued by the European Commission and by the European Medicines Agency (EMA), the decentralised agency of the EU responsible for the scientific evaluation, supervision and safety monitoring of medicines.

Regulation of medicinal products

Article 1(2) of Directive 2001/83/EC, the Pharmaceutical Code defines a medicinal product as a substance that is either:

•
presented as preventing or treating disease, or
•
used to correct or modify a physiological function by pharmacological, immunological or metabolic action, or to make a medical diagnosis

Practice Note: Introduction to the regulation of medicinal products—EU provides an

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest EU Law News

Council of the EU approves permanent lower liquidity requirements for short-term bank transactions

The Council of the EU has approved amendments to the Capital Requirements Regulation (Regulation (EU) 575/2013) to make permanent the transitional required stable funding (RSF) factors for certain short-term securities financing transactions (SFTs) used in calculating the net stable funding ratio (NSFR). The decision ensures these RSF factors remain below those set by the Basel III standards, supporting liquidity and market stability for EU banks. It also aims to prevent a competitive disadvantage for EU banks, as many non-EU jurisdictions already apply lower permanent SFT factors. The amendments will be published in the EU’s Official Journal and take effect from 29 June 2025. The European Banking Authority will monitor and report on their impact every five years.

Coreper endorses EU mandate to revise FDI screening rules

The Council of the EU, represented by Coreper, has endorsed a mandate to revise the Foreign Direct Investment (FDI) screening regulation. The revised regulation will require all Member States to implement harmonised screening mechanisms, establish a minimum sectoral scope, and extend coverage to include EU-based entities ultimately controlled by non-EU investors. Any restrictions imposed must be justified by serious public policy or security concerns. The Council has also supported anti-circumvention measures targeting intra-EU investments by foreign-controlled subsidiaries and has narrowed the regulation’s scope to focus on sensitive areas such as military and dual-use goods. The Council, the European Parliament, and the European Commission are set to begin interinstitutional negotiations to finalise the legislation.

Commission proposes further delay to market risk requirements under Basel III

The European Commission has adopted a delegated regulation under Regulation (EU) 575/2013 (EU CRR) to postpone by one additional—until 1 January 2027—the application of the Fundamental Review of the Trading Book (FRTB), the final component of the Basel III framework yet to be implemented in the EU. The delegated act was adopted following technical assessments and feedback from a recent public consultation. It responds to delays in the implementation of equivalent standards in other major jurisdictions and seeks to maintain a level international playing field for EU banks engaging in capital markets activities.

EBA revises its validation rules for supervisory reporting

The European Banking Authority (EBA) has revised its validation rules for supervisory reporting, effective 12 June 2025, deactivating certain rules due to errors and IT-related issues. Competent Authorities across the EU are advised not to validate data against these deactivated rules. To support this change, the EBA has released a validation package—including a micro taxonomy package and DPM VR deactivation update scripts—required from release 4.0 to ensure consistent rule management across the taxonomy and Data Point Model.